HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zydus Lifesciences Limited

https://www.zyduslife.com/index

Latest From Zydus Lifesciences Limited

Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh

Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.

Deal Watch Business Strategies

Lupin’s Confidence Over Mirabegron Relaunch Doesn’t Convince Analyst

While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.

Generic Drugs Launches

Lupin CEO Highlights Structural Support For Generics Pricing, Sees gMyrbetriq Relaunch

Lupin’s CEO spoke of US drug shortages having led to recognition of the need for structural and regulatory support for viable pricing of generic drugs. She was also optimistic on the relaunch of a Myrbetriq generic after Astellas obtained a temporary restraining order against Lupin and Zydus just a few days post an at-risk launch by the latter two companies

Commercial Sales & Earnings

US Court Provides Opportunity For Lupin And Zydus To Debut Generic Myrbetriq

Lupin and Zydus are targeting a market worth at least $1bn a year – and more than $2.4bn all told – after both in quick succession announcing the launch of generic versions of Astellas Pharma’s Myrbetriq treatment for overactive bladder.

Launches Intellectual Property
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Cadila Healthcare
    • Zydus Pharmaceuticals USA
    • German Remedies
    • Zynesher Pharmaceuticals USA LLC
    • Nesher Pharmaceuticals Inc
    • Quimica e Farmaceutica Nikkho do Brasil Ltda
    • Bremer Pharma GmbH
    • Nippon Universal Pharmaceuticals
    • Zydus Discovery DMCC
    • Zydus Urosciences
    • Sentynl Therapeutics, Inc
    • Zydus Lifesciences Ltd
    • Cadila Healthcare Ltd.
    • Zydus Cadila
UsernamePublicRestriction

Register